Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Treatment-Resistant Depression, Bipolar ...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the safety and initial effectiveness of MR-guided focused ultrasound (MRgFUS) bilateral capsulotomy in patients with treatment-resistant bipolar depression (TRBD).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: ExAblate Neuro 4000 — ExAblate Neuro 4000 is an MR-guided focused ultrasound (MRgFUS) device used to perform noninvasive thermal ablation of targeted brain tissue. In this study, ExAblate Neuro 4000 will be used to ablate the anterior limb of the internal capsule (capsulotomy) in patients with treatment-resistant bipolar depression (TRBD). The procedure is conducted under real-time MRI guidance and thermometry to assess safety and initial effectiveness in improving clinical symptoms and quality of life.

Primary Outcomes

  • Safety of Magnetic Resonance-guided Focused Ultrasound for patients with Treatment-Resistant Bipolar Disorder (From the treatment day visit through the 24-month post-treatment time points.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-25
Completion: 2028-07-16
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Contact Information
Study Contact:
Nir Lipsman, MD, PhD, FRCSC
(416)-480-6954
Nir.Lipsman@sunnybrook.ca
Anusha Baskaran, PhD
416-480-6100
anusha.baskaran@sunnybrook.ca
Interventions
  • Device: ExAblate Neuro 4000 — ExAblate Neuro 4000 is an MR-guided focused ultrasound (MRgFUS) device used to perform noninvasive thermal ablation of targeted brain tissue. In this study, ExAblate Neuro 4000 will be used to ablate the anterior limb of the internal capsule (capsulotomy) in patients with treatment-resistant bipolar depression (TRBD). The procedure is conducted under real-time MRI guidance and thermometry to assess safety and initial effectiveness in improving clinical symptoms and quality of life.
Study Locations (1 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: 1. Men and women ≥18 and ≤65 years of age, inclusive. 2. Patients who are competent and willing to give consent and able to attend study visits, as determined by both study Psychiatrist and the surgeon. 3. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of Bipolar Disorder, Type 1 or Type 2. 4. A minimum score of 20 on the Hamilton Depression Rating Scale (HAMD) when depressed (at least 2 weeks of major depression at the time the HAMD is conducted). 5. Treatment refractory bipolar depression indicated by at least two recommended monotherapy treatments or at least one monotherapy treatment and another combination treatment. The minimum duration for being on either of these regimens should be 4 weeks. 6. Ability to provide informed consent/competent to make medical decisions. Exclusion Criteria: Patients with unstable cardiac status \[e.g. Unstable angina pectoris on medication, Patients with documented myocardial infarction within six months, Congestive heart failure requiring medication (other than diuretic), Patients on anti-arrhythmic drugs, Severe hypertension (diastolic BP \> 100 on medication)\] 2. Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. 3\. Laboratory biochemical evidence of abnormal bleeding and/or coagulopathy, including risk factors for intraoperative or postoperative bleeding (platelet count less than 100,000 per cubic millimeter or abnormal International Normalized Ratio) 4. Cerebrovascular disease (e.g. Cerebrovascular Accident within 6 months) or history of intracranial hemorrhage. 5\. Untreated, uncontrolled sleep apnea. 6. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure. 7\. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment. 8\. Are participating or have participated in another clinical trial in the last 30 days. 9\. Patients unable to communicate with the investigator and staff. 10. Presence of significant cognitive impairment 11. History of psychosis on clinical evaluation. 12. Catatonic or psychotic or actively suicidal on clinical evaluation. 12. Patients with brain tumors already known or revealed on pretreatment MRI. 13. Currently pregnant (as determined by history and serum Human Chorionic Gonadotropin) or lactating. 14\. Chemical abuse or dependence within the previous six months
Conditions Anxiety, Depression, Behavior Problem
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Emotion Focused Family Therapy (EFFT) is a promising intervention that aims to teach parents advanced skills to support their child's development of emotion skills and increase their adaptive behaviours, potentially leading to improvements in their child's psychological functioning and family functioning more broadly. This randomized controlled trial (RCT; EFFT vs waitlist control) will (1) test the efficacy of a 6-week group EFFT program on parent and child outcomes and (2) examine maintenance of treatment gains up to four months post-intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Emotion Focused Family Therapy — The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment. Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks.

Primary Outcomes

  • Change in parental psychopathology symptoms at 6 weeks and 4 months (Change at 6 weeks; Change at 4 months)
  • Change in child psychopathology symptoms at 6 weeks and 4 months (Change at 6 weeks; Change at 4 months)
  • Change in parental emotion regulation at 6 weeks and 4 months (Change at 6 weeks; Change at 4 months)
  • Change in child emotion regulation at 6 weeks and 4 months (Change at 6 weeks; Change at 4 months)
  • Change in parent-child co-regulation at 6 weeks and 4 months (Change at 6 weeks; Change at 4 months)
  • Change in parent-child relationship functioning at 6 weeks and 4 months (Change at 6 weeks; Change at 4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-11
Completion: 2027-03
Eligibility
Age: 7 Years – 15 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Guelph
Principal Investigators:
  • Kristel Thomassin, Ph.D (PRINCIPAL_INVESTIGATOR) - University of Guelph
Contact Information
Study Contact:
Kristel Thomassin, Ph.D
519-824-4120
kristel.thomassin@uoguelph.ca
Jessica A Seddon, MSc
jseddon@uoguelph.ca
Interventions
  • Behavioral: Emotion Focused Family Therapy — The Emotion Focused Family Therapy (EFFT) intervention for this study will be delivered to groups of four to ten parents over six weekly sessions of two hours each. The goal of EFFT is to teach and empower parents to coach their child to process the emotions at the source of their mental health symptoms, to increase their child's adaptive behaviours, and to repair emotional injuries within the parent-child relationship. EFFT also targets parents' own emotional challenges that may prevent them from feeling capable or being able to support their child's treatment. Each EFFT session will include introductions, psychoeducation about emotion and psychopathology, introduction of skills, experiential activities (e.g., chair work), open discussion and feedback, and homework activities covering the foci of EFFT: emotion coaching, behaviour coaching, therapeutic apology, and parental emotion blocks.
Study Locations (1 sites)
Maplewoods Centre for Family Therapy and Child Psychology, University of Guelph, Guelph, Ontario N1G 4S7 Canada
Eligibility Criteria
Inclusion Criteria: * Parent of child aged 7 to 15 years old with anxiety, depression, or behavioural challenges * Parent of child is willing to participate in intervention * Parent is living at home with the child Exclusion Criteria: * Parent or child not proficient enough in speaking/understanding English to complete measures or EFFT intervention components * Parent or child with a severe mental health disorder (e.g., active suicidality and psychosis) is not considered suitable for the trial intervention due to the clinical need for immediate intervention * Parent or child is actively receiving, or due to receive, intensive psychological intervention focused on cognitive and/or behavioural strategies to intervene with emotional or behavioural difficulties * Parent or child has any disabilities in language, speech or hearing that would interfere with their completion of the EFFT and measures * Parent or child are allergic to adhesive electrode gel use in some tasks (i.e., sodium chloride)
Conditions Esophageal Varices
Phase NA
Enrollment 320
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled trial is to evaluate the cross-section band ligation technique versus the stepladder band ligation technique in esophageal varices prophylaxis. Researchers will compare cross-section and step ladder band ligation techniques for esophageal varices prophylaxis regarding efficacy, side effects, variceal recurrence, and survival. Participants will undergo history-taking, clinical examination, laboratory investigations, and upper endoscopy. Index upper endoscopy will be performed to evaluate the presence, size, and grade of esophageal varices. Patients will be randomly assigned to endoscopic band ligation (EBL) either by cross-section or stepladder techniques every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3-6 months to check for variceal recurrence. For a period of 6 months, all patients in the treatment groups will be followed up every 3 months with clinic visits, including laboratory testing, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Procedure: endoscopic band ligation with cross-section technique — Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the cross-section banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment.
  • Procedure: Endoscopic band ligation using stepladder technique — Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the stepladder banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment

Primary Outcomes

  • Vriceal bleeding rate at 6 weeks follow up (through study completion, an average of 1 year)
  • Mortality rate at 6 weeks follow up (through study completion, an average of 1 year)
  • Banding side effects at 6 weeks follow up (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-01
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 320 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Principal Investigators:
  • Nabila A Elgazzar, MD (PRINCIPAL_INVESTIGATOR) - Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University
Contact Information
Study Contact:
Rania M Elkafoury, MD
+201004672358
rania.elkafoury@med.tanta.edu.eg
Nabila A Elgazzar, MD
00201288585733
nabilaelgazzar@med.tanta.edu.eg
Dina H Ziada, MD
00201117109990
dina.ziada@med.tanta.edu.eg
Tanta University Hospitals
Interventions
  • Procedure: endoscopic band ligation with cross-section technique — Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the cross-section banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment.
  • Procedure: Endoscopic band ligation using stepladder technique — Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the stepladder banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment
Study Locations (1 sites)
Tanta University Hospitals, Tanta, Gharbyea 31516 Egypt
Eligibility Criteria
Inclusion Criteria: * Aged \>18 years. * Cirrhotic patients. * Endoscopic evidence of medium/large-sized esophageal varices. Exclusion Criteria: * History of variceal bleeding or previous primary prevention of varices. * Portal vein thrombosis or previous porto-systemic shunts as TIPS. * Patients on drugs affecting portal pressure (beta blockers, nitrates). * Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, and severe bradycardia. * Patients with severe respiratory diseases (COPD, bronchial asthma). * Uncontrolled diabetes mellitus. * Renal impairment. * Hepatocellular carcinoma. * Allergy to carvedilol. * Pregnancy or lactation.
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 2420
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The major goal of the study is to determine whether phonocardiography (using the Eko DUO stethoscope which can capture a three lead ECG reading) can present features that relate to the presence of PH diagnosed by echocardiography or right heart catheterization (RHC), and therefore have a potential to assist the provider to suspect PH.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Use of Eko DUO stethoscope (paired ECG/PCG) — Auscultation of heart sounds using electronic stethoscope

Primary Outcomes

  • Build a database of matched ECG/PCG recordings labeled against RHCs and echocardiograms (Up to 2 years to complete database)
  • Develop and clinically test a deep learning algorithm that can detect PH and stratify its severity (Up to 3 years to complete algorithm development)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-12
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eko Devices, Inc.
Principal Investigators:
  • Guarav Choudhary, MD (PRINCIPAL_INVESTIGATOR) - Lifespan
Contact Information
Study Contact:
Spencer Kieu
714-623-6652
spencer.kieu@ekohealth.com
Pamela Brewer, PhD, RN
401-273-71oo
Pamela.Brewer2@va.gov
Providence VA Medical Center
Interventions
  • Device: Use of Eko DUO stethoscope (paired ECG/PCG) — Auscultation of heart sounds using electronic stethoscope
Study Locations (3 sites)
Rhode Island Hospital, Providence, Rhode Island 02903 United States
The Miriam Hospital, Providence, Rhode Island 02906 United States
Providence VA Medical Center, Providence, Rhode Island 02908 United States
Eligibility Criteria
Inclusion Criteria: * Patients, ages \>18 years, referred for complete 2-dimensional echocardiography or right heart catheterization will be screened for inclusion. Exclusion Criteria: * Patients undergoing limited echocardiography * Intubated patients
Conditions Ocular Hypertension, Primary Open Angle ...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, single-masked, crossover, non-inferiority trial aims to evaluate the safety and efficacy of Nanodropper-mediated microdrops of ocular hypotensive topical treatments (experimental intervention) compared to standard drops of the same medication(s) (active comparator) in Wilford Hall Ambulatory Surgical Center (WHASC) primary open-angle glaucoma (POAG) and ocular hypertension (OHTN) patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Device: Nanodropper — Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
  • Device: Regular dropper — Delivers full eye drop volume

Primary Outcomes

  • Change from baseline in mean intraocular pressure at 6 month (Change from baseline to month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-03-17
Completion: 2024-03-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: 59th Medical Wing
Collaborators: Nanodropper, Inc.
Principal Investigators:
  • Alexandra Papp, MD (PRINCIPAL_INVESTIGATOR) - 59th Medical Wing
Contact Information
Study Contact:
Jose E Capo-Aponte, OD, PhD
210-292-2554
Jose.E.CapoAponte.ctr@health.mil
Jennifer Steger, PhD
507-405-5676
jenny@nanodropper.com
Jose E Capo-Aponte, OD, PhD
210-292-2554
Jose.E.CapoAponte.ctr@health.mil
Wilford Hall Ambulatory Surgical Center
Interventions
  • Device: Nanodropper — Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
  • Device: Regular dropper — Delivers full eye drop volume
Study Locations (1 sites)
Wilford Hall Ambulatory Surgical Center, Lackland Air Force Base, Texas 78236 United States
Eligibility Criteria
Inclusion Criteria: * POAG/OHTN patients above the age of 18 years. * On a maximum of 2 IOP lowering medications. * Stable disease without progression in IOP, optic disc cupping, RNFL changes, and visual field changes within the previous 1 year. Exclusion Criteria: * Glaucoma not of the POAG or OHTN variety or other retinal diseases. * Progression of disease within the preceding 1 year (IOP elevation, optic disc cupping, visual field changes). * Using more than 2 IOP-lowering medications. * IOP-lowering surgical interventions or lasers except for SLT. SLT may have been completed 6+ months prior to study start date.
Conditions Primary Open Angle Glaucoma (POAG)
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Primary open-angle glaucoma is a chronic optic neuropathy that often requires surgical intervention when medical treatment fails. Deep sclerectomy is a non-penetrating glaucoma surgery that aims to reduce intraocular pressure while minimizing complications. When combined with trabeculotomy, additional aqueous outflow may be achieved. Ultrasound biomicroscopy (UBM) allows detailed imaging of the anterior segment and provides valuable information about postoperative anatomical changes that cannot be assessed clinically. This observational study aims to evaluate UBM findings after combined deep sclerectomy with trabeculotomy in patients with primary open-angle glaucoma and to correlate these findings with clinical outcomes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Ultrasound Biomicroscopy — Ultrasound biomicroscopy is performed as a non-invasive diagnostic imaging procedure to evaluate postoperative anterior segment anatomy, including intrascleral lake characteristics and filtering bleb morphology, in patients with primary open-angle glaucoma following combined deep sclerectomy with trabeculotomy.

Primary Outcomes

  • Intrascleral lake area on ultrasound biomicroscopy (UBM) (3 and 6 months postoperatively)
  • Intrascleral lake height on ultrasound biomicroscopy (UBM) (3 and 6 months postoperatively)
  • Filtering bleb height on ultrasound biomicroscopy (UBM) (3 and 6 months postoperatively)
  • Filtering bleb internal reflectivity on ultrasound biomicroscopy (UBM) (3 and 6 months postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-11
Completion: 2026-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Minia University Hospital
Contact Information
Study Contact:
Ahmed Magdy Farouk, MD
+201551416518
ahmed.magdy1077@gmail.com
Minia University Hospital
Interventions
  • Diagnostic Test: Ultrasound Biomicroscopy — Ultrasound biomicroscopy is performed as a non-invasive diagnostic imaging procedure to evaluate postoperative anterior segment anatomy, including intrascleral lake characteristics and filtering bleb morphology, in patients with primary open-angle glaucoma following combined deep sclerectomy with trabeculotomy.
Study Locations (1 sites)
Minia University Hospital, Minya, Minya Governorate Egypt
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary open-angle glaucoma (POAG), including juvenile open-angle glaucoma (JOAG). * Patients who underwent combined deep sclerectomy with trabeculotomy. * Clear media allowing adequate ultrasound biomicroscopy imaging. * Written informed consent obtained from the patient . Exclusion Criteria: * Secondary glaucomas (e.g., neovascular, uveitic, traumatic, or angle-closure glaucoma). * Previous glaucoma filtering surgery in the studied eye. * Coexisting ocular pathology affecting UBM assessment (e.g., severe corneal opacity, scleral pathology).
Conditions Hyperglycaemia, Hypertension, Hyperlipid...
Phase NA
Enrollment 280
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are: 1. How satisfied are the patients and caregivers with this pharmacy chatbot? 2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists? There will be an intervention group and a control group: 1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social media platform in Hong Kong. They can inquire about their medications prescribed under HA and get instant, validated answers from the chatbot. 2. The control group will not use the chatbot during the intervention period. To evaluate the chatbot's usability, researchers will measure patient satisfaction through usability questionnaires issued to the intervention group after their intervention period. Differences in medication adherence, medication knowledge, and HA pharmacist consultation time will also be measured between the intervention and control groups after the intervention period, to determine the chatbot's impact.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: An AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia — It is a chatbot for HA-prescribed medication used for treating hyperglycaemia, hypertension, and hyperlipidaemia, available through WhatsApp. All the responses will be extracted from a database, in which the content was obtained from and validated by pharmacists from the Chief Pharmacist's Office of the Hospital Authority in Hong Kong. The intervention period will last for 7 days.

Primary Outcomes

  • Medical knowledge (1 week)
  • Medical adherence (1 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06
Completion: 2026-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 280 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: Laboratory of Data Discovery for Health, Hospital Authority, Hong Kong
Principal Investigators:
  • Joseph Wu, PhD (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Joseph Wu, PhD
+852 3917 6709
hkusph@hku.hk
Kathy Leung, PhD
+852 3917 6735
hkusph@hku.hk
Laboratory of Data Discovery for Health
Joseph Wu, PhD
Laboratory of Data Discovery for Health
Interventions
  • Other: An AI pharmacy chatbot offering information related to HA-prescribed medication for hyperglycaemia, hypertension, and hyperlipidaemia — It is a chatbot for HA-prescribed medication used for treating hyperglycaemia, hypertension, and hyperlipidaemia, available through WhatsApp. All the responses will be extracted from a database, in which the content was obtained from and validated by pharmacists from the Chief Pharmacist's Office of the Hospital Authority in Hong Kong. The intervention period will last for 7 days.
Study Locations (2 sites)
Laboratory of Data Discovery for Health, Hong Kong, Hong Kong
The University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong. * Caregivers aged 18 years or older for patients described above. Exclusion Criteria: * There is no exclusion criterion, but they should meet the inclusion criteria above.
Conditions Hypertension
Phase NA
Enrollment 750
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

HyperEcho is a multi-centre longitudinal observational study, to investigate whether baseline transthoracic echocardiography along with routine data collected in the hypertension clinic can guide clinicians to better manage, and improve risk stratification for cardiovascular disease in young adults with hypertension. Participants are characterised as young adult patients aged between 18 to 40 years old and referred to the hypertension clinic to manage their blood pressure. The study visit will be carried out during the planned routine visit of the participants to the hypertension clinics of NHS trusts within England. Routine data will be collected by the assigned nurse for the hypertension clinic as part of the clinical service, and research participation will not affect the clinical progress of the participant. The additional research component to the clinic will be asking the participants for their consent to undergo a research echocardiography scan if it has not been a part of their clinical assessment. Participants will also be asked to consent to the use of their data that has been collected in the hypertension clinic, such as; referral letters, medical history, 24-hour blood pressure monitoring report, ECG, blood samples, body fat composition, and dietary questionnaire. In addition to this, participants will be asked to consent to further review of their data and medical notes during their follow up visits (up to 10 years).

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Quadruple

Interventions / Regimen

  • Diagnostic Test: Echocardiography scan — Non-invasive ultrasound imaging of the heart.

Primary Outcomes

  • Identification of patient clusters based on echocardiographic and clinical findings (Obtained at the first clinical visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-10-02
Completion: 2038-08-01
Eligibility
Age: 18 Years – 40 Years
Sex: ALL
Volunteers: false
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oxford
Contact Information
Study Contact:
Maryam Alsharqi
+44(0)1865 572832
maryam.alsharqi@cardiov.ox.ac.uk
Maryam Alsharqi
+44(0)1865 572832
maryam.alsharqi@cardiov.ox.ac.uk
Cardiovascular Clinical Research Facility
Interventions
  • Diagnostic Test: Echocardiography scan — Non-invasive ultrasound imaging of the heart.
Study Locations (1 sites)
Cardiovascular Clinical Research Facility, Oxford, OX3 9DU United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 - 40 years (at the time of their appointment at the hypertension clinic). * Referred for a Hypertension Clinic in England. Exclusion Criteria: * Unable or unwilling to give valid consent for participation in the study.
Conditions Preeclampsia, Preeclampsia (PE), Preecla...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Hexadecadienoate (z score) (60 minutes after ingestion of 75 grams of glucose during a single study visit between 14-20 weeks gestational age)
  • Salicylate (z score) (60 minutes after ingestion of 75 grams of glucose during a single study visit between 14-20 weeks gestational age)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-12-31
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Tennessee Graduate School of Medicine
Contact Information
Study Contact:
Jill M Maples, PhD
865-305-9367
jmaples1@utmck.edu
Rebecca Purvis, MD
rpurvis@utmck.edu
University of Tennessee Medical Center
Interventions
N/A
Study Locations (1 sites)
University of Tennessee Medical Center, Knoxville, Tennessee 37920 United States
Eligibility Criteria
Inclusion Criteria: * Recommended aspirin for pre-eclampsia prevention by OB/GYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors) * Willingness to adhere to aspirin therapy * Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc. * Gestational age at enrollment \<16 weeks * Ability to speak, read, and communicate via English Exclusion Criteria: * Type 2 Diabetes Mellitus * Type 1 Diabetes Mellitus * Current gestational diabetes mellitus * Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.) * Thrombophilia * Current use of NSAID for other indication (indomethacin, ibuprofen, etc.) * Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.) * Current or recent use of steroids * Current use of prophylactic or therapeutic anticoagulation * Medical contraindication to aspirin therapy * Molar pregnancy * Renal disease * Inability or unwillingness to give informed consent * Current psychiatric illness/social situation that would limit compliance with study requirements, as determined by the principal investigators
Conditions Preeclampsia, Pregnant With Complication
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

High maternal mortality from preeclampsia/eclampsia results from a lack of early identification and management of pregnant women at high risk for preeclampsia. A potential tool to support pregnant women at high risk for preeclampsia is telemonitoring. Most telemonitoring interventions have been implemented in high-income countries and thus there is limited evidence on the use and effectiveness of telemonitoring for pregnant women in low-middle-income countries (LMICs). The scarce evidence on the feasibility of telemonitoring program implementation limits the understanding of the process and mechanisms through which the intervention works in LMICs. The study will explore the feasibility of implementing a mobile phone-based telemonitoring program for pregnant women at high-risk for preeclampsia in Karachi, Pakistan. The study will be conducted at the Jinnah Post Graduate Medical Center in Karachi, Pakistan. The study will use a mixed-methods design to recruit 50 pregnant women at high risk for preeclampsia to assess clinical feasibility across the five foci of Bowen's framework including acceptability, demand, implementation, practicality, and limited-efficacy testing. Data sources will include semi-structured interviews with the patients, and clinicians, as well as data from paper medical records, research logs, and server data. The results of the quantitative and qualitative data will be analyzed separately and then integrated at the interpretation and reporting levels to advance our understanding of the telemonitoring program's feasibility. This will be the first study to provide evidence on the feasibility of using a telemonitoring program where pregnant women at high-risk for preeclampsia in Pakistan will take their own blood pressure readings at home.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Raabta Telemonitoring Program (Mobile Application) — Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.

Primary Outcomes

  • Acceptability (At study completion, approximately 1 year)
  • Demand (At study completion, approximately 1 year)
  • Practicality (At study completion, approximately 1 year)
  • Fidelity (At study completion, approximately 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-04
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Collaborators: Jinnah Postgraduate Medical Centre, Aga Khan University, University of Toronto
Principal Investigators:
  • Emily Seto, PhD (PRINCIPAL_INVESTIGATOR) - University of Toronto
Contact Information
Study Contact:
Emily Seto, PhD
416-669-9295
emily.seto@utoronto.ca
Anam Shahil Feroz, MSc
6478676702
anam.shahil@mail.utoronto.ca
Haleema Yasmin
+92 21 99201300
dr.haleemayasmin@yahoo.com
Jinnah Postgraduate Medical Centre
Interventions
  • Other: Raabta Telemonitoring Program (Mobile Application) — Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
Study Locations (1 sites)
Jinnah Postgraduate Medical Centre, Karachi, Sindh 75510 Pakistan
Eligibility Criteria
Inclusion Criteria: * Pregnant women at high-risk for preeclampsia (HRPE) who are either in their first or second trimester of pregnancy. The definition of HRPE will follow that of the NICE guidelines that define pregnant women at HRPE as those who have one high-risk factor or more than one moderate risk factor for preeclampsia. * Participants who can speak and read (at least at a rudimentary level with help from a caregiver) the Urdu language for ease of communication with the research team and to be able to use the telemonitoring system. * Partners (almost always male husbands in the Pakistani culture) and/or other caregivers (e.g., mother and mother-in-law) of pregnant women \[for post-study interviews\] * Clinicians and nurses involved in the implementation of the telemonitoring program \[for post-study interviews\] Exclusion Criteria: * Pregnant women at high-risk for preeclampsia who are admitted to hospital for the management of their preeclampsia condition
Conditions AKI, CKD, Ckd-Mbd, CKD (Chronic Kidney D...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to: * AKI * CKD * Hypertension * ADPKD * CKD-MBD * Patients with decompensated heart failure undergoing either medical or surgery therapy * Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation * glomerular diseases

Design

Study type: Observational Observational model: Other Time perspective: Other

Interventions / Regimen

  • Genetic: genetic polymorphisms

Primary Outcomes

  • difference in glomerular filtration rate according to genetic profile (from days to 35 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2006-05-19
Completion: 2041-05-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ospedale San Raffaele
Contact Information
Study Contact:
Chiara Livia Lanzani, prof
+393408163279
lanzani.chiara@hsr.it
Laura Zagato, biologist
+390226435745
zagato.laura@hsr.it
Chiara Lanzani, MD
+390226433891
lanzani.chiara@hsr.it
IRCCS Ospedale San Raffaele
Interventions
  • Genetic: genetic polymorphisms
Study Locations (1 sites)
IRCCS Ospedale San Raffaele, Milan, 20132 Italy
Eligibility Criteria
Inclusion Criteria: . presence of specific renal disease Exclusion Criteria: * to be evaluated in the different sub-protocols
Conditions Hypertension
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension or high blood pressure is defined as when the pressure in the blood vessels is too high. According to Joint National Committee 8 (JNC 8) Guidelines, hypertension is defined as systolic blood pressure level of more than ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg. This study aims to study the combined effects of Pilates breathing, Diaphragmatic breathing and Moderate Intensity Continuous Cycling Training on blood pressure, chest expansion, pulmonary function and quality of life. Aerobic physical activity moderate intensity continuous training: (55%- 70% of maximal heart rate (MHR), rate of perceived exertion (RPE) of 11-13 on the Borg scale) continuous training, known as MICT. Pilates breathing exercise enhances lung expansion by focusing on controlled rhythmic breathing methods involving respiratory muscles. Diaphragmatic breathing exercise is slow and controlled deep breathing that has important effects on respiratory system by the modulation of autonomic nervous system. Hypertensive patients will be selected for this study. The study will include three groups. One group will undergo Cycling training with Pilates breathing and the other group will undergo Cycling training with Diaphragmatic breathing and third group will undergo Cycling training only. Before initiating the intervention at the baseline, following outcome measures would be assessed for all the patients: Blood pressure, chest expansion, pulmonary function and quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Cycling Training (Moderate-intensity continuous training) — Moderate-intensity continuous cycling training performed at 60-79% of maximum heart rate for 20-35 minutes, three sessions per week for six weeks.
  • Other: Pilates Breathing — Controlled lateral breathing technique focusing on rib cage expansion and core activation performed for 10-15 minutes. A 06 weeks protocol will be followed.
  • Other: Diaphragmatic Breathing — Slow deep breathing emphasizing diaphragmatic movement performed for 10-15 minutes. A 06 weeks protocol will be followed.

Primary Outcomes

  • Blood Pressure (SBP and DBP) (06 weeks)
  • Chest Expansion (06 weeks)
  • Pulmonary Function Test (06 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-12
Completion: 2026-05-15
Eligibility
Age: 20 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Foundation University Islamabad
Contact Information
Study Contact:
Saba Rehman, MSPT-CPT
03295200871
sabarehman278@gmail.com
Sana Bashir, PhD*
+923218529475
drsana.bashir@fui.edu.pk
Sana Bashir, PhD*
+923218529475
drsana.bashir@fui.edu.pk
Foundation University, Islamabad
Interventions
  • Other: Cycling Training (Moderate-intensity continuous training) — Moderate-intensity continuous cycling training performed at 60-79% of maximum heart rate for 20-35 minutes, three sessions per week for six weeks.
  • Other: Pilates Breathing — Controlled lateral breathing technique focusing on rib cage expansion and core activation performed for 10-15 minutes. A 06 weeks protocol will be followed.
  • Other: Diaphragmatic Breathing — Slow deep breathing emphasizing diaphragmatic movement performed for 10-15 minutes. A 06 weeks protocol will be followed.
Study Locations (1 sites)
Foundation University, Islamabad, Islamabad, Pakistan
Eligibility Criteria
Inclusion Criteria: * Medically diagnosed patients having Stage 1 hypertension(SBP;140-159 mmHg,DBP:90-99mmHg) and Stage 2 -hypertension(SBP:≥160mmHg,DBP:≥100mmHg) according to JNC 8 Guidelines, referred by a medical specialist or GP or cardiologist from FFH or clinical setups or Hospitals of Rawalpindi/Islambad * Patients who are on antihypertensive medications for at least 3 months before study. * Age ranging from 20-55 years * Both male and female patients. * Patients who are willing to participate in exercise regime and are able to -provide informed consent, have not been a part of any exercise regime from the last 6 months and well tolerated for exercise after being screened through PAR-Q+ Exclusion Criteria: * Patients with Stage 3 hypertension (SBP: ≥180 mmHg or DBP: ≥110 mmHg) and above hypertension according to JNC 8 Guidelines or Hypertensive Crisis etc. * Patients with any severe knee or other orthopedic conditions that can limit exercise performance * Patients with uncontrolled hypertension * History of any abdominal, orthopedic or spinal surgery that could interfere with core or breathing exercise * Neurological or psychiatric disorders * Uncontrolled cardiovascular conditions such as arrhythmias or recent myocardial infarction * Pregnant women